CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project aims to develop a dual-action malaria vaccine targeting both Plasmodium falciparum and Plasmodium vivax. It utilizes advanced vaccine technologies, including virus-like particles and mRNA, to enhance efficacy and facilitate large-scale production, ultimately contributing to malaria eradication efforts.
Malaria killed about 640 thousand people in 2020, largely young children in Africa.
Rapid recent progress has led to two anti-sporozoite vaccine developers planning WHO prequalification applications in 2022.
These include the new high efficacy R21/Matrix-M vaccine, to be supplied at the required large scale, and led by partners in this consortium.
In parallel, recent progress with transmission-blocking malaria vaccines has led to substantial efficacy in a first direct skin feeding field trial. T…
EUROPEAN VACCINE INITIATIVE EV
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Germany, Berlin
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Portugal, Oeiras
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Sweden, Uppsala
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: No
VACCINE FORMULATION INSTITUTE(CH)LTD
Switzerland, PLAN LES OUATES
Type: Other
Activity type: Other
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 sectors.
Guests see up to 5 keywords.
